Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline
- Series A financing led by Pfizer Ventures with new investors Columbus Venture Partners and British Patient Capital which join founding investor Advent Life Sciences and seed investor Epidarex Capital
- Goal to advance proprietary discovery platform and progress pipeline of assets addressing challenging cancer targets into the clinic
Southampton, UK, 27 February 2023 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the close of its successful £40.5 million Series A financing. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.
